{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:45:40Z","timestamp":1789422340393,"version":"build-2803163510"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) has become one of the important causes of cirrhosis and liver cancer, resulting in a huge medical burden worldwide. Currently, effective non-invasive diagnostic indicators and drugs for NAFLD are still lacking. With the development of metabolomics technology, the changes in metabolites during the development of NAFLD have been gradually revealed. Bile acid (BA) is the main endpoint of cholesterol metabolism in the body. In addition, it also acts as a signaling factor to regulate metabolism and inflammation in the body through the farnesyl X receptor and G protein-coupled BA receptor. Studies have shown that BA metabolism is associated with the development of NAFLD, but a large number of animal and clinical studies are still needed. BA homeostasis is maintained through multiple negative feedback loops and the enterohepatic circulation of BA. Recently, treatment of NAFLD by interfering with BA synthesis and metabolism has become a new research direction. Here, we review the changes in BA metabolism and its regulatory mechanisms during the development of NAFLD and describe the potential of studies exploring novel non-invasive diagnostic indicators and therapeutic targets for NAFLD based on BA metabolism.<\/jats:p>","DOI":"10.3389\/fmolb.2022.1089359","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T08:43:45Z","timestamp":1671093825000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["The role of bile acid metabolism in the occurrence and development of NAFLD"],"prefix":"10.3389","volume":"9","author":[{"given":"Hao","family":"Bing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1194\/jlr.RA119000395","article-title":"Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition","volume":"61","author":"Akira Honda","year":"2020","journal-title":"J. Lipid Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41579-021-00621-9","article-title":"Mass spectrometry-based metabolomics in microbiome investigations","volume":"20","author":"Bauermeister","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"E121","DOI":"10.1152\/ajpendo.00409.2016","article-title":"Cyp8b1 ablation prevents Western diet-induced weight gain and hepatic steatosis because of impaired fat absorption","volume":"313","author":"Bertaggia","year":"2017","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/apt.15035","article-title":"Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD","volume":"49","author":"Caussy","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1002\/jcb.27635","article-title":"Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics","volume":"120","author":"Chen","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","article-title":"Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy","volume":"318","author":"Chiang","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1124\/dmd.121.000643","article-title":"Molecular regulation of bile acid homeostasis","volume":"50","author":"Choudhuri","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.jhep.2021.01.028","article-title":"STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway","volume":"74","author":"Conde De La Rosa","year":"2021","journal-title":"J. Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1053\/gast.2001.25503","article-title":"The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp","volume":"121","author":"Denson","year":"2001","journal-title":"Gastroenterology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"11905","DOI":"10.3390\/ijms222111905","article-title":"Clinical and molecular biomarkers for diagnosis and staging of NAFLD","volume":"22","author":"Di Mauro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.apsb.2015.01.004","article-title":"Bile acid nuclear receptor FXR and digestive system diseases","volume":"5","author":"Ding","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered bile acid metabolome in patients with nonalcoholic steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"100387","DOI":"10.1016\/j.jhepr.2021.100387","article-title":"Bile acids contribute to the development of non-alcoholic steatohepatitis in mice","volume":"4","author":"Gillard","year":"2022","journal-title":"JHEP Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.apsb.2021.12.011","article-title":"Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases","volume":"12","author":"Guan","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.3390\/nu13072135","article-title":"Perinatal High-Salt diet induces gut microbiota dysbiosis, bile acid homeostasis disbalance, and NAFLD in weanling mice offspring","volume":"13","author":"Guo","year":"2021","journal-title":"Nutrients"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.2337\/db13-0639","article-title":"Human insulin resistance is associated with increased plasma levels of 12\u03b1-Hydroxylated bile acids","volume":"62","author":"Haeusler","year":"2013","journal-title":"Diabetes"},{"key":"B19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","article-title":"Epidemiology and risk-stratification of NAFLD-associated HCC","volume":"75","author":"Ioannou","year":"2021","journal-title":"J. Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s13238-020-00804-9","article-title":"Targeting the alternative bile acid synthetic pathway for metabolic diseases","volume":"12","author":"Jia","year":"2021","journal-title":"Protein Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.bbadis.2018.05.011","article-title":"Animal models to study bile acid metabolism","volume":"1865","author":"Jianing Li","year":"2019","journal-title":"Biochim. Biophys. Acta. Mol. Basis Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"key":"B24","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1152\/physiolgenomics.00011.2021","article-title":"Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD","volume":"53","author":"Jiao","year":"2021","journal-title":"Physiol. Genomics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.3390\/antiox10122001","article-title":"The synbiotic combination of akkermansia muciniphila and quercetin ameliorates early obesity and NAFLD through gut microbiota reshaping and bile acid metabolism modulation","volume":"12","author":"Ju\u00e1rez-Fern\u00e1ndez","year":"2021","journal-title":"Antioxidants"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1111\/liv.15030","article-title":"Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus","volume":"41","author":"Jung","year":"2021","journal-title":"Liver Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.metabol.2010.03.006","article-title":"Plasma metabolomic profile in nonalcoholic fatty liver disease","volume":"60","author":"Kalhan","year":"2011","journal-title":"Metabolism."},{"key":"B28","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: A clinical review","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin. Res. Cardiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.3390\/ijms23116046","article-title":"Molecular basis of bile Acid-FXR-FGF15\/19 signaling axis","volume":"23","author":"Katafuchi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"5969","DOI":"10.1038\/s41467-020-19803-9","article-title":"Intestinal FGF15\/19 physiologically repress hepatic lipogenesis in the late fed-state by activating SHP and DNMT3A","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"B31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.taap.2013.01.022","article-title":"Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease","volume":"268","author":"Lake","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/nu14010095","article-title":"Soybean-Derived peptides attenuate hyperlipidemia by regulating Trans-Intestinal cholesterol excretion and bile acid synthesis","volume":"14","author":"Lee","year":"2022","journal-title":"Nutrients"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e202200146","DOI":"10.1002\/cbdv.202200146","article-title":"Dihydroflavonoids as bioactive components ofPenthorum chinense, a miao ethnomedicine, against NAFLD through bile acid metabolism pathway","volume":"19","author":"Li","year":"2022","journal-title":"Chem. Biodivers."},{"key":"B34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3892\/ijo.2022.5407","article-title":"Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids (Review)","volume":"61","author":"Luo","year":"2022","journal-title":"Int. J. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0115521","DOI":"10.1128\/mBio.01155-21","article-title":"Ileal bile acid transporter inhibitor improves hepatic steatosis by ameliorating gut microbiota dysbiosis in NAFLD model mice","volume":"12","author":"Matsui","year":"2021","journal-title":"mBio"},{"key":"B36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.tem.2017.11.002","article-title":"Role of bile acids in metabolic control","volume":"29","author":"Molinaro","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"key":"B37","doi-asserted-by":"publisher","first-page":"154457","DOI":"10.1016\/j.metabol.2020.154457","article-title":"Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression","volume":"116","author":"Nimer","year":"2021","journal-title":"Metabolism."},{"key":"B38","doi-asserted-by":"publisher","first-page":"154320","DOI":"10.1016\/j.metabol.2020.154320","article-title":"The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease","author":"Perakakis","year":"2020","journal-title":"Metabolism."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/cphy.c210024","article-title":"Bile acids, gut microbiome and the road to fatty liver disease","volume":"12","author":"Phillip B Hylemon","year":"2021","journal-title":"Compr. Physiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"357ra122","DOI":"10.1126\/scitranslmed.aaf4823","article-title":"Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet\u2013fed mice","volume":"8","author":"Rao","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1021\/acs.jproteome.0c00852","article-title":"Bile acid profiles are distinct among patients with different etiologies of chronic liver disease","volume":"20","author":"Sang","year":"2021","journal-title":"J. Proteome Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab."},{"key":"B44","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1084\/jem.20171965","article-title":"Bile acids in glucose metabolism in health and disease","volume":"215","author":"Shapiro","year":"2018","journal-title":"J. Exp. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"114664","DOI":"10.1016\/j.taap.2019.114664","article-title":"Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis","volume":"379","author":"Suga","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jhep.2022.02.030","article-title":"Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis","volume":"77","author":"Sun","year":"2022","journal-title":"J. Hepatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e00131","DOI":"10.14309\/ctg.0000000000000131","article-title":"Altered microbiota diversity and bile acid signaling in cirrhotic and noncirrhotic NASH-HCC","volume":"11","author":"Sydor","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1194\/jlr.M071183","article-title":"Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans","volume":"57","author":"Takahashi","year":"2016","journal-title":"J. Lipid Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1074\/jbc.RA119.011913","article-title":"Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet\u2013fed mice","volume":"295","author":"Takahashi","year":"2020","journal-title":"J. Biol. Chem."},{"key":"B50","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/hep.25630","article-title":"Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis","volume":"56","author":"Tanaka","year":"2012","journal-title":"Hepatology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/hep.28991","article-title":"New therapeutic concepts in bile acid transport and signaling for management of cholestasis","volume":"65","author":"Trauner","year":"2017","journal-title":"Hepatology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","article-title":"Novel therapeutic targets for cholestatic and fatty liver disease","volume":"71","author":"Trauner","year":"2021","journal-title":"Gut"},{"key":"B53","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism","volume":"24","author":"Wahlstr\u00f6m","year":"2016","journal-title":"Cell Metab."},{"key":"B54","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12902-022-01155-8","article-title":"Uygur type 2 diabetes patient fecal microbiota transplantation disrupts blood glucose and bile acid levels by changing the ability of the intestinal flora to metabolize bile acids in C57BL\/6 mice","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Endocr. Disord."},{"key":"B55","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jare.2021.06.001","article-title":"Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism","volume":"34","author":"Wang","year":"2021","journal-title":"J. Adv. Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/hep4.1665","article-title":"Serum bile acid, vitamin e, and serotonin metabolites are associated with future liver\u2010related events in nonalcoholic fatty liver disease","volume":"5","author":"Wegermann","year":"2021","journal-title":"Hepatol. Commun."},{"key":"B57","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1021\/acs.jproteome.1c00104","article-title":"Serum bile acid profiles improve clinical prediction of nonalcoholic fatty liver in T2DM patients","volume":"20","author":"Wu","year":"2021","journal-title":"J. Proteome Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"120152","DOI":"10.1016\/j.lfs.2021.120152","article-title":"Bile acids as regulatory molecules and potential targets in metabolic diseases","volume":"287","author":"Xie","year":"","journal-title":"Life Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"103290","DOI":"10.1016\/j.ebiom.2021.103290","article-title":"Conjugated secondary 12\u03b1-hydroxylated bile acids promote liver fibrogenesis","volume":"66","author":"Xie","year":"","journal-title":"EBioMedicine"},{"key":"B60","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s12072-020-10107-0","article-title":"Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice","volume":"15","author":"Yamauchi","year":"2021","journal-title":"Hepatol. Int."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1124\/dmd.118.082008","article-title":"Glycyrrhizin alleviates nonalcoholic steatohepatitis via modulating bile acids and meta-inflammation","volume":"46","author":"Yan","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"B62","doi-asserted-by":"publisher","first-page":"10858","DOI":"10.3390\/ijms221910858","article-title":"Flaxseed powder attenuates Non-Alcoholic steatohepatitis via modulation of gut microbiota and bile acid metabolism through gut\u2013liver axis","volume":"22","author":"Yang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"B64","doi-asserted-by":"publisher","first-page":"G549","DOI":"10.1152\/ajpgi.00152.2020","article-title":"Bile acid metabolism and circadian rhythms","volume":"319","author":"Yunxia Yang","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B65","first-page":"13485","article-title":"Bile acid metabolism and liver fibrosis following treatment with bifid triple viable capsules in nonalcoholic fatty liver disease","volume":"13","author":"Zhou","year":"2021","journal-title":"Am. J. Transl. Res."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2022.1089359\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T08:43:48Z","timestamp":1671093828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2022.1089359\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":65,"alternative-id":["10.3389\/fmolb.2022.1089359"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2022.1089359","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]},"article-number":"1089359"}}